Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization

Purpose Human epidermal growth factor receptor-2 (HER2) status can be tested with immunohistochemistry (IHC) and in situ hybridization (ISH). The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing guidelines suggest initial HER2 testing using IHC and further testing IHC equivocal cases with ISH. However, many institutions perform both IHC and ISH on the same specimen. This study aims to analyze the concordance between HER2 IHC and ISH in order to evaluate the benefit of repeating HER2 testing on the same breast cancer specimens.Method Patients diagnosed with invasive breast cancer through BreastScreen NSW Sydney West program between January 2018 and December 2020 were identified and their HER2 IHC and HER2 ISH results on core needle biopsy (CNB) and surgical excisions (SE) were retrospectively collected. Specimens with both IHC and ISH results were then analyzed for agreement and concordance using unweighted kappa values. Equivocal IHC (2+) cases were excluded from concordance analysis.Results Overall, there were 240 invasive breast cancer specimens (CNB and SE) with both IHC and ISH recorded. Concordance between HER2 IHC and ISH was 100% (95% CI: 96.2-100%; kappa = 1.00 (P < 0.001)). Of the IHC equivocal cases (n = 146), 94.5% were ISH negative.Conclusion There was perfect positive concordance and agreement between non-equivocal IHC and ISH results. This reinforces that IHC alone can be utilized reliably for testing HER2 status of non-equivocal cases consistent with the 2018 ASCO/CAP guidelines.

Automated summary

The study aimed to analyze the concordance between HER2 immunohistochemistry (IHC) and in situ hybridization (ISH) and evaluate the benefit of repeating HER2 testing on the same breast cancer specimens. The results showed perfect positive concordance and agreement between non-equivocal IHC and ISH results, indicating that IHC alone can be reliably used for HER2 status testing based on the 2018 ASCO/CAP guidelines.